Lung Cancer, Non-Hodgkin Lymphoma Biggest Contributors to Life-Years Lost to Cancer in Transplant Patients Lung Cancer, Non-Hodgkin Lymphoma Biggest Contributors to Life-Years Lost to Cancer in Transplant Patients
Transplant recipients have a shortened lifespan after developing cancer, especially those who develop lung cancer and non-Hodgkin lymphoma, according to a new analysis.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - September 22, 2021 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news
FDA Approval for Zanubrutinib in Waldenstr öm’s Macroglobulinemia FDA Approval for Zanubrutinib in Waldenstr öm’s Macroglobulinemia
The US Food and Drug Administration has approved zanubrutinib for use in the treatment of adult patients with a rare form of non-Hodgkin lymphoma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous trials.â...
Source: Roche Media News - August 9, 2021 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous trials.â...
Source: Roche Investor Update - August 9, 2021 Category: Pharmaceuticals Source Type: news
Researchers discover a novel class of drugs that may help treat a deadly type of lymphoma
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A new class of drugs that inhibits a 'master switch' involved in the vast majority of cases of mantle cell lymphoma (MCL), a fatal subtype of non-Hodgkin's lymphoma, has been discovered by researchers at Mount Sinai. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 22, 2021 Category: Biology Source Type: news
Prolonged COVID-19 Common Among Patients With Lymphoma Prolonged COVID-19 Common Among Patients With Lymphoma
Approximately a third of patients with B-cell non-Hodgkin lymphoma require hospitalization for COVID-19 beyond 30 days. Older age and anti-CD20 therapy are key risk factors.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Durham company sees promise in clinical trials for leukemia treatment
A gene therapy company's interim clinical trial results for a leukemia treatment have company executives optimistic about the treatment's future.
Durham-based Precision BioSciences (Nasdaq: DTIL) last week announced the interim results of the phase 1/2a trial for PBCAR0191, which showed 75 percent of the study participants with treatment-resistant non-Hodgkins lymphoma responded to the company's treatment.
PBCAR0191 is an allogeneic chime ric antigen receptor T cell, or CAR-T, therapy that uses… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 14, 2021 Category: American Health Authors: Sonia Waraich Source Type: news
Durham company sees promise in clinical trials for leukemia treatment
A gene therapy company's interim clinical trial results for a leukemia treatment have company executives optimistic about the treatment's future.
Durham-based Precision BioSciences (Nasdaq: DTIL) last week announced the interim results of the phase 1/2a trial for PBCAR0191, which showed 75 percent of the study participants with treatment-resistant non-Hodgkins lymphoma responded to the company's treatment.
PBCAR0191 is an allogeneic chime ric antigen receptor T cell, or CAR-T, therapy that uses… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 8, 2021 Category: Pharmaceuticals Authors: Sonia Waraich Source Type: news
Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma
Basel, 4 June 2021 ‒ Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data on its investigational CD20xCD3 T-cell engaging bispecific antibodies, mosunetuzumab and glofitamab, and its first-in-class anti-CD79b antibody-drug conjugate, Polivy® (polatuzumab vedotin), in non-Hodgkin lymphoma (NHL) will be p resented at the 2021 ASCO Annual Meeting from 4-8 June 2021. (Source: Roche Media News)
Source: Roche Media News - June 4, 2021 Category: Pharmaceuticals Source Type: news
Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma
Basel, 4 June 2021 ‒ Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data on its investigational CD20xCD3 T-cell engaging bispecific antibodies, mosunetuzumab and glofitamab, and its first-in-class anti-CD79b antibody-drug conjugate, Polivy® (polatuzumab vedotin), in non-Hodgkin lymphoma (NHL) will be p resented at the 2021 ASCO Annual Meeting from 4-8 June 2021. (Source: Roche Investor Update)
Source: Roche Investor Update - June 4, 2021 Category: Pharmaceuticals Source Type: news
Bayer loses appeal of $25 million verdict, making more Roundup lawsuits likely
Bayer lost its appeal of a $25 million ruling that Roundup caused a California man's non-Hodgkins lymphoma. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 17, 2021 Category: Pharmaceuticals Authors: Greg Edwards Source Type: news
Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
Basel, 11 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held 4-8 June, 2021. A total of 132 abstracts that include a Roche medicine will be presented at this year ' s meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types.“We will be presenting data from across our diverse oncology portfolio that has the potential to help...
Source: Roche Media News - May 11, 2021 Category: Pharmaceuticals Source Type: news
Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
Basel, 11 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held 4-8 June, 2021. A total of 132 abstracts that include a Roche medicine will be presented at this year ' s meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types.“We will be presenting data from across our diverse oncology portfolio that has the potential to help...
Source: Roche Investor Update - May 11, 2021 Category: Pharmaceuticals Source Type: news
Combo Provides'Broad Benefit' Across NHL Subtypes Combo Provides'Broad Benefit' Across NHL Subtypes
The combination of copanlisib + rituximab led to a reduction in the risk for disease progression/death when compared with rituximab + placebo in patients with relapsed, indolent non-Hodgkin lymphoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma
TUESDAY, April 13, 2021 -- Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 13, 2021 Category: Pharmaceuticals Source Type: news
